AMENDMENT No. 6

AMENDMENT NO. 6, dated as of March 30, 2026 (this “Amendment”), by and among LUMEXA IMAGING, INC., a Delaware corporation (the “LII Borrower”), LUMEXA IMAGING OUTPATIENT, INC., a Delaware corporation (the “LIO Borrower” and together with the LII Borrower, the “Borrowers”) and Barclays Bank PLC, as administrative agent (in such capacity, including any successor thereto, the “Administrative Agent”).

W I T N E S S E T H

WHEREAS, pursuant to that certain Credit Agreement, dated as of December 15, 2020 (as amended or otherwise modified by Incremental Amendment No. 1, dated as of December 31, 2021, Amendment No. 2, dated as of March 21, 2023, Amendment No. 3, dated as of July 16, 2024, Amendment No. 4, dated as of November 22, 2024, Amendment No. 5, dated as of December 17, 2025 and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”), by and among the Borrowers, Lumexa Imaging Intermediate Holdings, Inc., a Delaware corporation, Lumexa Imaging Outpatient Intermediate Ho

…

EMPLOYEE FORM

Name of Participant:		[__________]
Number of Shares of Stock subject to the SAR:		[__________]
Exercise Price Per Share:		$[__________]
Date of Grant:		[__________]
Original Grant Date		[__________]

WATERS CORPORATION

2026 EQUITY BASED COMPENSATION PLAN

GLOBAL SAR AWARD AGREEMENT

This agreement (this “Agreement”) including any appendix hereto containing country-specific terms and conditions (each an “Appendix”, and collectively the “Appendices”) evidences a stock appreciation right granted by Waters Corporation (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms and conditions of the Waters Corporation 2026 Equity-Based Compensation Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.

…

EMPLOYEE FORM

Name of Participant:		[____]
Number of Restricted Stock Units:		[____]
Date of Grant:		[____]
Original Grant Date		[____]

WATERS CORPORATION

2026 EQUITY BASED COMPENSATION PLAN

GLOBAL RESTRICTED STOCK UNIT AWARD AGREEMENT

This agreement (this “Agreement”) including the appendices hereto containing general terms and conditions for Participants outside the United States and country-specific terms and conditions (each an “Appendix,” and collectively the “Appendices”) evidences Restricted Stock Units granted by Waters Corporation (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms and conditions of the Waters Corporation 2026 Equity Based Compensation Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.

…

Five American

Lane Greenwich, CT 06831

April 15, 2025 Valeri Liborski

Delivered via email

Dear Valeri,

On behalf of QXO, Inc. (the “Company”), I am happy to offer you the position of Chief Technology Officer. I know I speak for the rest of our team when I say how pleased we are to make you this offer.

In this role, you will report directly to Brad Jacobs, Chief Executive Officer, and you will be based out of Bellevue, Washington or its vicinity once office space becomes available, with regular travel expected to the Greenwich, Connecticut office and across locations and geographies in which the Company transacts or pursues business. The start of your employment with the Company (the “Start Date”) is expected to be April 21, 2025.

Your salary and compensation

We’d like to offer you the following compensation package:

•Base Salary: Your initial annual base salary will be $650,000, less all applicable withholdings and deductions, and pro-rated for any partial period worked.

…

CERTAIN PERSONAL INFORMATION IN THIS EXHIBIT, MARKED BY [*], HAS BEEN REDACTED PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K.

March 26, 2026

Eric Loumeau

[*]

Re: Terms of Separation

Dear Eric:

This letter confirms the agreement (“Agreement”) between you and AnaptysBio, Inc. (the “Company” or “Anaptys”) concerning the terms of your mutual separation and offers you the separation compensation below in exchange for a general release of claims and covenant not to sue. If you choose to enter into this Agreement, please sign below, on March 26, 2026.

Separation Date; Transition Services:

a.

Separation Date: Your last day of employment with the Company will be the date on which the Company completes the distribution to its stockholders of shares of common stock of First Tracks Biotherapeutics, Inc. (“TRAX”) (the “Separation Date”).

b.

…

CERTAIN PERSONAL INFORMATION IN THIS EXHIBIT, MARKED BY [*], HAS BEEN REDACTED PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K.

March 26, 2026

Dennis Mulroy

[*]

Re: Terms of Separation

Dear Dennis:

This letter confirms the agreement (“Agreement”) between you and AnaptysBio, Inc. (the “Company”) concerning the terms of your mutual separation and offers you the separation compensation below in exchange for a general release of claims and covenant not to sue. If you choose to enter into this Agreement, please sign below on March 26, 2026.

Separation Date; Transition Services:

a.

Separation Date: Your last day of employment with the Company will be the date on which the Company completes the distribution to its stockholders of shares of common stock of First Tracks Biotherapeutics, Inc. (“TRAX”) (the “Separation Date”).

b.

…

CERTAIN PERSONAL INFORMATION IN THIS EXHIBIT, MARKED BY [*], HAS BEEN REDACTED PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K.

CONSULTING AGREEMENT

This Consulting Agreement (“Agreement”) is entered into as of April 20, 2026, (the “Effective Date”), between AnaptysBio, Inc., a Delaware corporation having its principal place of business in San Diego, California (“Company” or “Anaptys”), and Daniel Faga, an individual whose address is [*] (“Consultant”, and collectively with the Company, the “Parties”).

WHEREAS, the Company will complete a distribution to its stockholders of shares of common stock of First Tracks Biotherapeutics, Inc. (“TRAX”), a wholly owned subsidiary of the Company (the “Transaction”), which is anticipated to be completed on April 20, 2026;

WHEREAS, TRAX is a newly formed public company; and

WHEREAS, Consultant has agreed to provide consulting services to the Company following the Transaction, on the terms and conditions set forth in this Agreement;

…

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE CMPETITIVE HARM TO ANABTYSBIO, INC. IF PUBLICLY DISCLOSED.

Exhibit 10.1

AMENDMENT NO. 6 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT

This Amendment No. 6 to the Collaboration and Exclusive License Agreement (this “Amendment”) is dated as of April 10, 2026 and effective as of January 30, 2026 (the “Amendment Date”), is entered into by and between (a) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10770 Wateridge Circle, Suite 210, San Diego, California 92121 (“AnaptysBio”), and (b) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO”). Collectively, AnaptysBio and TESARO are referred to as the “Parties” and, individually, as a “Party.” All capitalize

…

SIDE LETTER AGREEMENT

May 7, 2026

This Side Letter Agreement (this “Side Letter Agreement”), dated as of May 7, 2026, is by and between CID Holdco, Inc. (the “Company”) and White Lion Capital, LLC (“White Lion”). The Company and White Lion are collectively referred to herein as the “Parties”.

Reference is made to that certain Note Purchase Agreement (the “Note Purchase Agreement”), dated April 17, 2026, by and between the Parties. Capitalized terms used but not defined herein shall have the definitions ascribed to them by the Note Purchase Agreement.

In consideration of the mutual agreements contained herein, the Parties hereby agree as follows:

1. Amendments to Note Purchase Agreement. White Lion and the Company acknowledge and agree to the following terms and conditions in addition to those set forth in the Note Purchase Agreement:

…

July 15, 2025

VIA EMAIL ONLY

Dear Susan:

This letter sets forth our agreement (the "Letter Agreement") regarding advisory services to be provided

by you to the Board of Directors of Andersen Group Inc. ("AGI") and your eventual service as a director on the Board of AGI.

1.Effective as of July 16, 2025, you will act as an advisor ("Advisor") to the Board of Directors of AGI, a Delaware corporation until such time as you become a director ("Director") on the Board of AGI which shall occur by no later than July 1, 2026, unless either party provides the other with reasonable advance written notice of termination of your services as an Advisor or Director at any time.

2.Remuneration as follows:

…

FOURTH AMENDED AND RESTATED INVESTMENT ADVISORY

AND MANAGEMENT AGREEMENT

BETWEEN

ARES STRATEGIC INCOME FUND

AND

ARES CAPITAL MANAGEMENT LLC

This Fourth Amended and Restated Investment Advisory and Management Agreement (this “Agreement”), dated as of May 12, 2026 and effective as of June 6, 2026 (the “Effective Date”), is made by and between Ares Strategic Income Fund, a Delaware statutory trust (the “Fund”), and Ares Capital Management LLC, a Delaware limited liability company (the “Adviser”).

WHEREAS, the Fund is a closed-end management investment company that has elected to be treated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “Investment Company Act”);

WHEREAS, the Adviser is an investment adviser that has registered under the Investment Advisers Act of 1940, as amended (the “Advisers Act”);

…

THIS INSTRUMENT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THIS INSTRUMENT MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.

SECURED PROMISSORY NOTE

$510,000.00		March 11, 2026

FOR VALUE RECEIVED, GROWN ROGUE MANAGEMENT ASSOCIATES LLC, an Illinois limited liability company (“Borrower”), hereby unconditionally promise to pay to the order of FOREFATHERS VENTURES, LLC, an Illinois limited liability company (“Holder”), the principal amount of Five Hundred Ten Thousand Dollars ($510,000.00) (the “Principal Amount”), together with interest thereon as set forth herein.

…